NCT03605550View on ClinicalTrials.gov

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2029

Conditions
High Grade GliomaDiffuse Intrinsic Pontine Glioma
Interventions
DRUG

PTC596

Oral tablets

RADIATION

Radiotherapy

Cycle1

Trial Locations (10)

19104

The Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

PTC Therapeutics
All Listed Sponsors
collaborator

PTC Therapeutics

INDUSTRY

lead

Nationwide Children's Hospital

OTHER

NCT03605550 - A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Biotech Hunter | Biotech Hunter